{"links":{"feed":"https://www.erudio.com/reports/horizon-lung-nct04818333/feed.json","html":"https://www.erudio.com/reports/horizon-lung-nct04818333","json":"https://www.erudio.com/reports/horizon-lung-nct04818333.json","markdown":"https://www.erudio.com/reports/horizon-lung-nct04818333.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"horizon-lung-nct04818333"}},"request":"https://www.erudio.com/contact?report=horizon-lung-nct04818333"},"offer":{"cited_clinicians":3,"cited_commentary_sources":13,"verified_hcp_statements":50,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":4},"for_sale":true,"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person; ask them for their work email and organization, both required. It returns the quote, a checkout_url for your person to pay by card and a pay_url your own payment client can pay over HTTP 402, with MPP (USDC on Tempo) or x402 (USDC on Base). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"required: the buyer's company or institution","product":["edition","updates-3","updates-6","updates-12"],"report":"horizon-lung-nct04818333"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. Or pay it yourself: POST pay_url answers 402 Payment Required with both agent payment standards, MPP (USDC on Tempo) and x402 (USDC on Base); your payment client pays one. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=horizon-lung-nct04818333","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/horizon-lung-nct04818333","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 50 verified statements · 9 from 3 confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-21T09:08:28.642147Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":10,"no_commentary_found":4},"aspects":[{"claim_count":0,"coverage":"no_commentary_found","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":0,"title":"Primary endpoint: Phase 1:Incidence of Adverse Events (AEs) by CTCAE v5.0 of SHR-A1811"},{"claim_count":0,"coverage":"no_commentary_found","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":0,"title":"Primary endpoint: Phase 1:Severity of Adverse Events (AEs) by CTCAE v5.0 of SHR-A1811"},{"claim_count":0,"coverage":"no_commentary_found","id":"T3","registry_field":"outcomesModule.primaryOutcomes[2]","source_count":0,"title":"Primary endpoint: Phase1: Maximum tolerated dose (MTD)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T4","registry_field":"outcomesModule.primaryOutcomes[3]","source_count":0,"title":"Primary endpoint: Phase 1: Recommended Phase 2 dose (RP2D)"},{"claim_count":6,"coverage":"discussed","id":"T5","registry_field":"outcomesModule.primaryOutcomes[4]","source_count":9,"title":"Primary endpoint: Phase2:ObjectiveResponse Rate (ORR)"},{"claim_count":5,"coverage":"discussed","id":"T6","registry_field":"outcomesModule.secondaryOutcomes","source_count":8,"title":"Secondary endpoints"},{"claim_count":8,"coverage":"discussed","id":"T7","registry_field":"conditionsModule","source_count":11,"title":"Population and setting"},{"claim_count":2,"coverage":"discussed","id":"T8","registry_field":"armsInterventionsModule.armGroups","source_count":2,"title":"The comparison"},{"claim_count":4,"coverage":"discussed","id":"T9","registry_field":"outcomesModule","source_count":7,"title":"Safety and tolerability"},{"claim_count":2,"coverage":"discussed","id":"T10","registry_field":"designModule","source_count":2,"title":"Design and conduct"},{"claim_count":3,"coverage":"discussed","id":"A1","source_count":3,"title":"Clinical niche and differentiation from other HER2-directed options"},{"claim_count":2,"coverage":"discussed","id":"A2","source_count":2,"title":"ADC classification and design framing"},{"claim_count":1,"coverage":"discussed","id":"A3","source_count":1,"title":"Related AACR25 drug commentary after chemo-immunotherapy"},{"claim_count":1,"coverage":"discussed","id":"A4","source_count":1,"title":"First-line phase III development beyond the reported population"}],"counts":{"cited_clinicians":3,"cited_clinicians_by_role":{"physician":1,"physician, Medical oncology":2},"cited_physicians":3,"cited_sources":15,"claims_by_expression_type":{"comparison":4,"interpretation":19,"opinion":5,"primary_context":6,"question":2,"restatement":6,"uncertainty":7,"unspecified":1},"claims_by_kind":{"objective_result":4,"protocol_statement":2,"publication_statement":25,"source_observation":19},"clinician_statements":9,"evidence_units":52,"findings":3,"organisational_accounts":3,"people_cited":5,"people_identity_verified":4,"people_total":5,"screened_sources":37,"verified_claims":50},"findings_index":[{"cited_clinicians":1,"id":"F1","structure":{"claims":7,"claims_by_group":{"comparisons":2,"experience":0,"questions":1,"restated":3,"views":1},"limitations":2,"links":{"context":1,"support":13},"ma_question":true,"named_voices":2,"passages":12,"sources":4,"sources_by_kind":{"commentary":1,"media":1,"publication":2}},"title":"Another HER2 ADC: a clinician questions its need and place in treatment","title_holders":{"cited_claim_ids":["claim-bef9c5303fa1b881d4a8"],"clinicians":true,"holders":1,"speakers":2,"view":"reading"},"evidence_line":"7 statements from 2 speakers in 4 sources, 1 of them a podcast or video","holder_line":"1 of the 2 named speakers in this finding holds this view, a confirmed clinician"},{"cited_clinicians":3,"id":"F2","structure":{"claims":16,"claims_by_group":{"comparisons":0,"experience":0,"questions":3,"restated":5,"views":8},"limitations":4,"links":{"context":5,"support":17},"ma_question":true,"named_voices":4,"passages":15,"sources":10,"sources_by_kind":{"commentary":7,"media":1,"publication":2}},"title":"HORIZON-Lung: what speakers highlight in response rates after prior therapy","title_holders":{"cited_claim_ids":["claim-10ed064bb8c5c73071b9","claim-185caa1d096364949b6f","claim-1506a877382384a38b17","claim-f711112606ed2ccd55ce","claim-b658b15f0daf77cdc732","claim-cfbc708e22b822025320"],"clinicians":false,"holders":4,"speakers":4,"view":"reading"},"evidence_line":"16 statements from 4 speakers in 10 sources, 1 of them a podcast or video","holder_line":"4 of the 4 named speakers in this finding hold this view"},{"cited_clinicians":2,"id":"F3","structure":{"claims":9,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":5,"views":2},"limitations":3,"links":{"context":1,"support":14},"ma_question":true,"named_voices":3,"passages":11,"sources":10,"sources_by_kind":{"commentary":8,"publication":2}},"title":"Responses: what speakers say","evidence_line":"9 statements from 3 speakers in 10 sources"}],"open_question":{"basis":"From finding F1 (7 statements from 2 speakers in 4 sources)","cited_claim_ids":["claim-10ed064bb8c5c73071b9","claim-bef9c5303fa1b881d4a8","claim-8d6fb591dfae85ed278e","claim-db63d87e6d8c3272496f","claim-2dd0f38af695406fe16e","claim-0ad268b3ab73d8a3eb86","claim-411f4553be25436d024d"],"finding_ids":["F1"],"question":"What do clinicians still need to see from HORIZON-Lung to define the niche for trastuzumab rezetecan (SHR-A1811) among HER2-directed ADCs in advanced HER2-mutant NSCLC after platinum-based chemotherapy and anti-PD-(L)1 treatment?"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"One podcast speaker asks what another HER2 ADC would add"},{"id":"section-2","level":2,"title":"Clinicians welcome activity, while other accounts describe therapeutic promise"},{"id":"section-3","level":2,"title":"X accounts include pulmonary and hematological risks in favorable summaries"},{"id":"section-4","level":2,"title":"Scope and coverage of the reviewed discussion"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, na, single group, phase1, phase2","trial_dimensions":[{"findings":[],"id":"T1","label":"Primary endpoint: Phase 1:Incidence of Adverse Events (AEs) by CTCAE v5.0 of SHR-A1811"},{"findings":[],"id":"T2","label":"Primary endpoint: Phase 1:Severity of Adverse Events (AEs) by CTCAE v5.0 of SHR-A1811"},{"findings":[],"id":"T3","label":"Primary endpoint: Phase1: Maximum tolerated dose (MTD)"},{"findings":[],"id":"T4","label":"Primary endpoint: Phase 1: Recommended Phase 2 dose (RP2D)"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":4},{"id":"F3","shared_claims":3}],"id":"T5","label":"Primary endpoint: Phase2:ObjectiveResponse Rate (ORR)"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":2}],"id":"T6","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":6},{"id":"F3","shared_claims":3}],"id":"T7","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":1}],"id":"T8","label":"The comparison"},{"findings":[{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":4}],"id":"T9","label":"Safety and tolerability"},{"findings":[{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":1}],"id":"T10","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-21T09:08:28.642147Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-21T09:20:12Z","record_hash":"f7aa35dcc5511f050116bcbf0796597be643fc8d37bc2cbdeca02a1965220917","release_hash":"6c7023d034c1451c2376fc272f3ae2892a737ad8d16de31265ef15d76e60e493","report_id":"erudio-nct04818333","run_id":"9e30257f-f269-496e-8378-8faf6a1d28b0","schema_version":"5.0","slug":"horizon-lung-nct04818333","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"The clinicians cited read HORIZON-Lung favorably for its tumor responses, while a physician remains undecided about its place among HER2-directed ADCs. Differing interstitial lung disease summaries are not necessarily equivalent safety measures, and the emphasis on low discontinuation does not establish negligible pulmonary risk. The separate first-line comparison with chemo-immunotherapy is mentioned without comparative outcomes, not as evidence for moving treatment earlier.","examples":[],"meta_description":"37 sources screened · 50 verified statements (9 from clinicians verified by NPI or staff page) from 15 sources · 3 findings. Updated Nov 21, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-21T09:20:12Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":37},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","1 clinician view in the sources used in this report is not yet captured as evidence in this edition.","47 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 34 sources about other trials or topics are not included.","Public podcast and X discussion cannot establish how common these opinions are or whether they have changed routine treatment choices.","Repeated posts from one unnamed account and reposts do not add independent clinician opinions. Organizational summaries and relayed wording are not equivalent to individually expressed HCP assessments.","Clinical roles are not established for several account authors. Source-described credentials or roles should not be treated as independently confirmed.","Differing ILD percentages and response-duration descriptions are preserved as attributed. The sources do not fully reconcile their definitions or reporting time points.","The reported clinical populations discussed here were HER2-mutant. The views do not establish benefit in HER2-overexpressing or amplified-only NSCLC, after another HER2 ADC, or in untreated or active CNS disease.","The first-line phase III update concerns a separate study. The relevant post does not name HORIZON-Lung, and no first-line comparative outcomes are provided in that statement.","No standalone trial protocol or exact regulatory label for SHR-A1811 was available in the sources reviewed, limiting fuller assessment of protocol details and regulatory positioning."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":1,"publication":2,"registry":0,"regulatory":0,"x_thread":12,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":13,"results":2},"count":15,"evidence_window":{"end":"2025-05-07","start":"2025-02-26"},"retrieval_snapshot":"2026-11-21T08:34:59.138955Z","timeline":[{"count":7,"week":"2025-W09"},{"count":1,"week":"2025-W11"},{"count":1,"week":"2025-W12"},{"count":1,"week":"2025-W17"},{"count":2,"week":"2025-W18"},{"count":1,"week":"2025-W19"}],"undated_sources":2},"quote_policies":[{"id":"clinicaltrials:NCT04818333:methods","quote_policy":"short_quote_link_out"},{"id":"pubmed:39004647","quote_policy":"short_quote_link_out"},{"id":"pubmed:40020696","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7326211925908844544","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:a20454","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1894553257810563215:5104868a-99c9-4b86-a13d-5d369b12aef4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1894555295462166719:3a8923bb-c863-4d97-a2cd-738fc67301f3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1894556485327421699:2971b99c-0166-42a9-b864-2a2c37b734c2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1894557056423924215:64fdaf74-af30-41f3-99cf-a1cb19f40afc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1894569043828363390:399bd718-053e-4d38-b6b6-3bdc8207953a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1894633163898368331:5bdaf277-6f1b-487c-8324-25ae084148c3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1894686844891046284:adb43c3e-1fa1-439a-b2cc-c7e03e7c0ac0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1894734182695518338:b59e55a4-a81c-4ea9-9a3a-db3bbb0ff659","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1894735248945979706:ff0c7d81-8471-41dc-b9dc-38eee4f11ee8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1894735505268310381:eba4063a-3df8-448b-a554-ade71b305abf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1894873415284334836:334e5281-379d-429f-a0f6-67df5228553c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1895039268126343572:25bd216f-e95d-459c-a4bc-aaed8a759cf9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1896659645894418695:5462ceb7-ffd2-4060-a6e5-e731a7e7d37e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1897954920017403913:4e077f74-1c7f-452f-b261-fe1e60e963c5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1898224157864640996:c8a08f93-306d-4adc-adf2-feafaa80f49c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1899897950588842330:8db8a6e5-4a35-4476-8890-1b8140f3b776","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1900877896459108692:ab3d1772-9d84-4bae-9855-d402e1fdd5c4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1901630602132242899:30b11e00-9a78-488e-9ab3-4893427a0868","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1901634665208778957:7b66ab81-d3b9-4ef4-ab8f-b19149475629","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1903094685381562769:398461c8-0d65-4a8a-b351-4fb3113606a3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1915048326929723628:254cb518-8b1d-4035-9adf-7d6c62a82646","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1915405379221282910:67416633-61a6-41c0-8d8a-6b5294f83d10","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1915482674329747837:3570bb65-3457-4a50-b833-7ce44a4e61bc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1916114275468259445:efe82cea-a65e-488d-aaf9-15bf670ef26a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1916115114186416274:0990fd3e-f0d5-4fcd-9529-6879f4b26055","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1916540921543315692:2c84693f-7bf0-4963-b75e-a80369bb6a77","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1916861591477260486:71fd511a-065a-4719-8e56-0c360408d9c1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1916943662799609902:b7700e1d-fbc6-4864-8556-ff07aac32795","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1917278829242114428:1ce844a8-5bfb-4ac3-97f5-edceeffb528d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1920103321907679257:66345fc8-0403-4558-8e06-df1e02c30e6e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1928099637262446920:ff2295dd-2d33-41f7-a889-448096447897","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1928889777979535455:4dcde520-3e06-420b-a0e3-52d29bad0f02","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1928906185513558173:4873f0bc-5898-45ce-9e3b-d54f34e2eb53","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1935976892500226468:9a9fdd72-42e1-4147-aba0-fb2a3b5c224e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098201260407263709:3ea85f0b-3a17-4ddc-948a-55b147993afc","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":1,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":35,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":37},"count":37,"evidence_window":{"end":"2026-09-11","start":"2025-02-26"},"retrieval_snapshot":"2026-11-21T08:34:59.138955Z","timeline":[{"count":12,"week":"2025-W09"},{"count":3,"week":"2025-W10"},{"count":2,"week":"2025-W11"},{"count":3,"week":"2025-W12"},{"count":1,"week":"2025-W13"},{"count":6,"week":"2025-W17"},{"count":4,"week":"2025-W18"},{"count":2,"week":"2025-W19"},{"count":3,"week":"2025-W22"},{"count":1,"week":"2025-W25"},{"count":1,"week":"2026-W37"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":3,"publication":31,"registry":0,"regulatory":0,"x_thread":16,"x_video":0,"youtube":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"brand_names":{"reason":"No checked-in brand mapping.","status":"unmapped"},"label":"trastuzumab rezetecan","slug":"trastuzumab-rezetecan"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Non-small cell lung cancer","slug":"non-small-cell-lung-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"HORIZON-Lung","aliases":["HORIZON-Lung","SHR-A1811-I-103","A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer","Phase I/II Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of SHR-A1811 for Injection in Subjects With Advanced Non-small Cell Lung Cancer Who Have HER2 Expression , Amplification, or Mutation"],"brief_title":"A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Advanced Non-small Cell Lung Cancer"],"display_condition":"advanced HER2-mutant non-small cell lung cancer","display_interventions":[["trastuzumab rezetecan (SHR-A1811)"]],"enrollment":{"count":157,"type":"ACTUAL"},"interventions":[{"name":"SHR-A1811","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT04818333","official_title":"Phase I/II Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of SHR-A1811 for Injection in Subjects With Advanced Non-small Cell Lung Cancer Who Have HER2 Expression , Amplification, or Mutation","overall_status":"UNKNOWN","phase":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2025-06","type":"ESTIMATED"},"primary_endpoints":[{"description":"Assess safety and tolerability of SHR-A1811 by way of adverse events (CTCAE v5.0)","measure":"Phase 1:Incidence of Adverse Events (AEs) by CTCAE v5.0 of SHR-A1811","timeFrame":"From Day 1 to90 days after last dose ，appropriately to 3 years"},{"description":"Assess safety and tolerability of SHR-A1811 by way of adverse events (CTCAE v5.0)","measure":"Phase 1:Severity of Adverse Events (AEs) by CTCAE v5.0 of SHR-A1811","timeFrame":"From Day 1 to90 days after last dose ，appropriately to 3 years"},{"description":"Incidence rate and category of dose limiting toxicities (DLTs) during the first 21-day cycle of SHR-A1811 treatment","measure":"Phase1: Maximum tolerated dose (MTD)","timeFrame":"12 months"},{"description":"RP2D was determined based on the safety, tolerability, PK, immunogenicity data and efficacy information obtained","measure":"Phase 1: Recommended Phase 2 dose (RP2D)","timeFrame":"12 months"},{"description":"As assessed by RECIST v1.1 , as assessed by independent review committee (IRC)","measure":"Phase2:ObjectiveResponse Rate (ORR)","timeFrame":"Subjects were evaluated on tumor imaging every 6 weeks after treatment initiation and every 12 weeks after 54 weeks, until imaging progression, initiation of new antitumor therapy, loss of follow-up, and death，appropriately to 3 years"}],"registered_date":{"date":"2021-03-26","type":"ACTUAL"},"registry_last_updated":"2024-06-13","registry_url":"https://clinicaltrials.gov/study/NCT04818333","short_name":"HORIZON-Lung","short_name_basis":"canonical_name","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","start_date":{"date":"2021-04-23","type":"ACTUAL"},"study_design":"interventional, na, single group, phase1, phase2","study_ids":[{"id":"SHR-A1811-I-103","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}